Abstract
We report 3 cases of allogeneic bone marrow transplantation in multiple myeloma that we have recently performed. Following conditioning treatment with i.v. cyclophosphamide (60 mg/kg/d, for 2 d), oral melphalan (1.0 mg/kg/d, for 5 d), i.v. BCNU (5.5 mg/kg, in a single dose) and total body irradiation (10 Gy in a single fraction) we observed in all 3 cases the disappearance both of serum M component and of monoclonal bone marrow plasma cells. 1 patient died of actue GVH disease, grade IV, at 2 months, while the other 2 patients are in good health and in unmaintained complete remission at 4 and 20 months, respectively. The usefulness of allogeneic bone marrow transplantation in the management of multiple myeloma is emphasized.
| Original language | English |
|---|---|
| Pages (from-to) | 176-179 |
| Number of pages | 4 |
| Journal | Scandinavian Journal of Haematology |
| Volume | 36 |
| Issue number | 2 |
| Publication status | Published - 1986 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Bone marrow transplantation in multiple myeloma. / Tura, S.; Cavo, M.; Baccarani, M.; Ricci, P.; Gobbi, M.
In: Scandinavian Journal of Haematology, Vol. 36, No. 2, 1986, p. 176-179.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bone marrow transplantation in multiple myeloma
AU - Tura, S.
AU - Cavo, M.
AU - Baccarani, M.
AU - Ricci, P.
AU - Gobbi, M.
PY - 1986
Y1 - 1986
N2 - We report 3 cases of allogeneic bone marrow transplantation in multiple myeloma that we have recently performed. Following conditioning treatment with i.v. cyclophosphamide (60 mg/kg/d, for 2 d), oral melphalan (1.0 mg/kg/d, for 5 d), i.v. BCNU (5.5 mg/kg, in a single dose) and total body irradiation (10 Gy in a single fraction) we observed in all 3 cases the disappearance both of serum M component and of monoclonal bone marrow plasma cells. 1 patient died of actue GVH disease, grade IV, at 2 months, while the other 2 patients are in good health and in unmaintained complete remission at 4 and 20 months, respectively. The usefulness of allogeneic bone marrow transplantation in the management of multiple myeloma is emphasized.
AB - We report 3 cases of allogeneic bone marrow transplantation in multiple myeloma that we have recently performed. Following conditioning treatment with i.v. cyclophosphamide (60 mg/kg/d, for 2 d), oral melphalan (1.0 mg/kg/d, for 5 d), i.v. BCNU (5.5 mg/kg, in a single dose) and total body irradiation (10 Gy in a single fraction) we observed in all 3 cases the disappearance both of serum M component and of monoclonal bone marrow plasma cells. 1 patient died of actue GVH disease, grade IV, at 2 months, while the other 2 patients are in good health and in unmaintained complete remission at 4 and 20 months, respectively. The usefulness of allogeneic bone marrow transplantation in the management of multiple myeloma is emphasized.
UR - http://www.scopus.com/inward/record.url?scp=0022608809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022608809&partnerID=8YFLogxK
M3 - Article
VL - 36
SP - 176
EP - 179
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 2
ER -